Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M384Revenue $M34.7Net Margin (%)-123.3Z-Score-46.8
Enterprise Value $M362EPS $-0.4Operating Margin %-119.8F-Score5
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-125.6Higher ROA y-yY
Price/Book42.710-y EBITDA Growth Rate %-46.6Quick Ratio1.6Cash flow > EarningsY
Price/Sales9.55-y EBITDA Growth Rate %-45.0Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-45.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-94.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M150ROI % (ttm)-75.7Gross Margin Increase y-yY

Gurus Latest Trades with CTIC

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CTIC is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CTIC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIANCO JAMES APresident and CEO 2014-08-15Sell40,000$2.54-0.39 view
Plunkett MatthewEVP, Corporate Development 2014-08-04Sell12,000$2.482.02 view
BIANCO LOUIS AEVP, Finance & Administration 2014-07-10Sell10,000$2.73-7.33 view
Plunkett MatthewEVP, Corporate Development 2014-07-07Sell12,000$2.89-12.46 view
BIANCO JAMES APresident and CEO 2014-06-27Sell50,000$2.84-10.92 view
BIANCO LOUIS AEVP, Finance & Administration 2014-06-05Sell10,000$2.97-14.81 view
BIANCO JAMES APresident and CEO 2014-06-04Sell55,000$2.99-15.38 view
Plunkett MatthewEVP, Corporate Development 2014-06-04Sell12,000$3.02-16.23 view
Plunkett MatthewEVP, Corporate Development 2014-05-05Sell12,000$2.96-14.53 view
BIANCO LOUIS AEVP, Finance & Administration 2014-05-01Sell10,000$2.91-13.06 view

Press Releases about CTIC :

    Quarterly/Annual Reports about CTIC:

    News about CTIC:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
    comment on CTIC Dec 16 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
    Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
    Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

    More From Other Websites
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 28 2014
    CTI BIOPHARMA CORP Financials Aug 09 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 07 2014
    FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the... Aug 07 2014
    CTI BioPharma upgraded by WallachBeth Aug 05 2014
    CTI BioPharma Corp Earnings Call scheduled for 4:30 pm ET today Aug 04 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 04 2014
    CTI BioPharma Reports Second Quarter 2014 Financial Results Aug 04 2014
    Q2 2014 CTi Biopharma Corp Earnings Release - After Market Close Aug 04 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jul 31 2014
    The Federal Reserve Playing Analyst Damaging to Biotechnology Companies Jul 30 2014
    CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 Jul 28 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 21 2014
    CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In... Jul 21 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 01 2014
    CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients... Jul 01 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 30 2014
    BrainStorm Cell, Octane construct bioreactor prototype for NurOwn Jun 27 2014
    CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 12 2014
    CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates... Jun 12 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK